PIVKA-II:一种新型乙型肝炎相关肝癌诊断标记物研究进展

doi:10.3969/j.issn.1672-5069.2022.04.038

摘要/Abstract

摘要： 目的病毒性肝炎,尤其是乙型肝炎病毒(HBV)感染是肝细胞癌(HCC)的主要致病因素。因缺乏早期症状,大部分HCC患者确诊时已为中晚期,因此预后不良。早诊断、早治疗是肝癌诊治的重要环节,现有的监测方法似乎不能显著提高肝癌的检出率。研究证实,维生素K缺失或拮抗剂-II诱导的蛋白质(PIVKA-II)有利于肝癌的早期诊断,本文对此进行了文献复习和综述。

关键词: 肝细胞癌, 乙型肝炎病毒, 维生素K缺失或拮抗剂-II诱导的蛋白质, 生物标志物, 诊断

Abstract: Objective Hepatocellar carcinoma (HCC) is still a heavy health burden in China. Hepatitis B and C infection is the main cause for it. Most patients with HCC are diagnosed at advanced stage with poor prognosis, owing to the lack of early symptoms. The present available monitoring approaches seem to unable to find liver cancer early. It is urgent to explore more sensitive markers to facilitate the early screening of liver cancer. The current research confirms that protein induced by vitamin K absence (PIVKA-II) is conducive to solving the problem. In this paper, we reviewed the progress on PIVKA-II as a new biological marker in this field.

Key words: Hepatocellar carcinoma, Hepatitis B virus, Protein induced by vitamin K absence, Biomarkers, Diagnosis

金盼盼, 张岭漪. PIVKA-II:一种新型乙型肝炎相关肝癌诊断标记物研究进展[J]. 实用肝脏病杂志, 2022, 25(4): 605-608.

Jin Panpan, Zhang Lingyi. PIVKA-II: a new biological marker in diagnosis of patients with hepatitis B-related hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2022, 25(4): 605-608.

参考文献

[1] Xie D Y, Ren Z G, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr, 2020,9(4):452-463.
[2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018,391(10127):1301-1314.
[3] Vo Q E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int, 2021,41(5):915-927.
[4] Li W, Deng R, Liu S, et al. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: the emerging role of non-viral risk factors. Liver Int, 2020,40(10):2316-2325.
[5] Luo P, Wu S, Yu Y, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res, 2020,26(2):599-603.
[6] Tsuchiya N, Sawada Y, Endo I, et al. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J Gastroenterol, 2015,21(37):10573-10583.
[7] Park S J, Jang J Y, Jeong S W, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore), 2017,96(11):e5811.
[8] Si Y Q, Wang X Q, Fan G, et al. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation. Infect Agent Cancer, 2020,15(1):70.
[9] Wu J, Xiang Z, Bai L, et al. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. Cancer Biomark, 2018,23(2):235-242.
[10] Xing H, Zheng Y J, Han J, et al. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: a systematic review with meta-analysis. Hepatobiliary Pancreat Dis Int, 2018,17(6):487-495.
[11] Liu Z, Wu M, Lin D, et al. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. J Int Med Res, 2020,48(2):1220702127.
[12] Durazo F A, Blatt L M, Corey W G, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol, 2008,23(10):1541-1548.
[13] 杨国荣, 朱月莲, 周宇, 等. PIVKA-Ⅱ对乙肝相关性原发性肝癌诊断价值的临床研究. 中国现代普通外科进展, 2021,24(08):608-611.
[14] Wong G L, Lampertico P. Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - is one NUC better than the other? J Hepatol, 2019,71(3):453-455.
[15] Shinn B J, Martin A, Coben R M, et al. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: the need for hepatitis B virus cure. World J Hepatol, 2019,11(1):65-73.
[16] Lin D, Yang H I, Nguyen N, et al. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients. Aliment Pharmacol Ther, 2016,44(8):846-855.
[17] Loglio A, Iavarone M, Facchetti F, et al. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV Caucasian cirrhotics on long-term oral therapy. Liver Int, 2020,40(8):1987-1996.
[18] Sun T, Li R, Qiu Y, et al. New thresholds for AFP and des-gamma-carboxy prothrombin in chronic liver disease depending on the use of nucleoside analogs and an integrated nomogram. Int J Gen Med, 2021,14:6149-6165.
[19] Song T, Wang L, Xin R, et al. Evaluation of serum AFP and DCP levels in the diagnosis of early-stage HBV-related HCC under different backgrounds. J Int Med Res, 2020,48(10):1220768639.
[20] Choi J, Kim G A, Han S, et al. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology, 2019,69(5):1983-1994.
[21] Wang G, Lu X, Du Q, et al. Diagnostic value of the gamma-glutamyltransferase and alanine transaminase ratio, alpha-fetoprotein, and protein induced by vitamin K absence or antagonist II in hepatitis B virus-related hepatocellular carcinoma. Sci Rep, 2020,10(1):13519.
[22] Caviglia G P, Abate M L, Gaia S, et al. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. Panminerva Med, 2017,59(4):283-289.
[23] Fujikawa T, Shiraha H, Ueda N, et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem, 2007,282(12):8741-8748.
[24] Yamashita Y I, Imai K, Yusa T, et al. Microvascular invasion of single small hepatocellular carcinoma </=3 cm: predictors and optimal treatments. Ann Gastroenterol Surg, 2018,2(3):197-203.
[25] Ma X L, Zhu J, Wu J, et al. Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol Lett, 2018,15(6):8396-8404.
[26] Pote N, Cauchy F, Albuquerque M, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol, 2015,62(4):848-854.
[27] Bhatti A, Naz K, Abbas G, et al. Clinical utility of protein induced by vitamin K absence-II in patients with hepatocellular carcinoma. Asian Pac J Cancer Prev, 2021,22(6):1731-1736.
[28] Li T, Yu Y, Liu J, et al. PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma. Infect Agent Cancer, 2019,14:13.
[29] Kang S H, Kim D Y, Jeon S M, et al. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Eur J Gastroenterol Hepatol, 2012,24(7):849-856.
[30] Chon Y E, Choi G H, Lee M H, et al. Combined measurement of preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer, 2012,131(10):2332-2341.
[31] Meguro M, Mizuguchi T, Nishidate T, et al. Prognostic roles of preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma patients. World J Gastroenterol, 2015,21(16):4933-4945.
[32] Lee S, Rhim H, Kim Y S, et al. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma. Liver Int, 2016,36(4):580-587.